CO5580751A2 - Nueva formulacion de jarabe de epinastina seco y acuoso - Google Patents

Nueva formulacion de jarabe de epinastina seco y acuoso

Info

Publication number
CO5580751A2
CO5580751A2 CO04042457A CO04042457A CO5580751A2 CO 5580751 A2 CO5580751 A2 CO 5580751A2 CO 04042457 A CO04042457 A CO 04042457A CO 04042457 A CO04042457 A CO 04042457A CO 5580751 A2 CO5580751 A2 CO 5580751A2
Authority
CO
Colombia
Prior art keywords
mask
powder formulation
pharmaceutical powder
acid
formulation according
Prior art date
Application number
CO04042457A
Other languages
English (en)
Inventor
Wada Koichio
Nakatani Manabu
Ohki Toshimitsu
Toyoshima Kenzo
Original Assignee
Boehrienger Ingelheim Internat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehrienger Ingelheim Internat filed Critical Boehrienger Ingelheim Internat
Publication of CO5580751A2 publication Critical patent/CO5580751A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

1.- Formulación farmacéutica en polvo, que comprende un agente activo basado en epinastina y/o una sal de adición de ácido, preferentemente el hidrocloruro, al menos dos tipos de edulcorantes y/o saborizantes, y opcionalmente otros coadyuvantes aceptables farmacéuticamente, en la que uno de los al menos dos tipos de edulcorantes y/o saborizantes es para enmascarar el amargor de acción rápida del agente activo y el otro es enmascarar el amargor de acción prolongada del agente activo.2.- Formulación farmacéutica en polvo según la reivindicación 1, caracterizada porque el al menos un edulcorante y/o saborizante para enmascarar el amargor de acción rápida se elige entre sacarina sódica, eritritol, aspartamo y/o azúcares u otros polioles tales como sacarosa, glicerina, D-sorbitol y D-manitol.3.- Formulación farmacéutica en polvo según las reivindicaciones 1 o 2, caracterizada porque el al menos un edulcorante y/o saborizante para enmascarar el amargor de acción rápida se elige entre sacarina sódica, eritritol y aspartamo.4.- Formulación farmacéutica en polvo según las reivindicaciones 1 a 3, caracterizada porque el al menos un edulcorante y/o saborizante para enmascarar el amargor de acción rápida es una combinación de sacarina sódica, eritritol y aspartamo. 5.- Formulación farmacéutica en polvo según cualquiera de las reivindicaciones 1 a 4, caracterizada porque el al menos un edulcorante y/o saborizante para enmascarar el amargor de acción prolongada es un glicirricinato o ácido glicirricínico, preferentemente elegido entre glicirricinato mono- o di-amónico, glicirricinato di- o tri-sódico y/o glicirricinaco potásico, lo más preferentemente glicirricinato monoamónico.6.- Formulación farmacéutica en polvo según cualquiera de las reivindicaciones 1 a 5, caracterizada porque la formulación comprende además un agente de ajuste del pH elegido entre el grupo de ácido cítrico, citratos, ácido succínico, ácido tartárico, ácido acético, acetatos, vitamina C, ácido clorhídrico, carbonatos, hidróxido sódico, cálcico, potásico y/o magnésico, fosfatos, preferentemente fosfato monosódico y/o fosfato disódico, lo más preferentemente fosfato monosódico.
CO04042457A 2001-10-26 2004-05-07 Nueva formulacion de jarabe de epinastina seco y acuoso CO5580751A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10152973A DE10152973A1 (de) 2001-10-26 2001-10-26 Neue trockene und wässrige Epinastin-Sirup-Formulierung

Publications (1)

Publication Number Publication Date
CO5580751A2 true CO5580751A2 (es) 2005-11-30

Family

ID=7703856

Family Applications (1)

Application Number Title Priority Date Filing Date
CO04042457A CO5580751A2 (es) 2001-10-26 2004-05-07 Nueva formulacion de jarabe de epinastina seco y acuoso

Country Status (9)

Country Link
EP (1) EP1448204A1 (es)
JP (2) JP4564749B2 (es)
KR (1) KR20050034619A (es)
BR (1) BR0213488A (es)
CO (1) CO5580751A2 (es)
DE (1) DE10152973A1 (es)
EC (1) ECSP045087A (es)
MX (1) MXPA04003772A (es)
WO (1) WO2003037350A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452177A1 (en) * 2003-02-27 2004-09-01 Boehringer Ingelheim International GmbH Pharmaceutical formulations comprising sodium laurylsulfate as bitterness masking agent
US20040247686A1 (en) * 2003-04-04 2004-12-09 Boehringer Ingelheim International Gmbh Pharmaceutical compositions comprising epinastine for the treatment of skin diseases
WO2005089803A2 (en) * 2004-03-24 2005-09-29 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment of skin diseases comprising a combination of epinastine and one or more additional minerals or one or more crude drugs
JP5132090B2 (ja) * 2006-06-16 2013-01-30 東和薬品株式会社 塩酸エピナスチンドライシロップ剤
CN105708808B (zh) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀颗粒剂及其制备方法
CN105708840A (zh) * 2014-12-01 2016-06-29 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀组合物
CN105708807B (zh) * 2014-12-01 2018-11-27 重庆安格龙翔医药科技有限公司 一种盐酸依匹斯汀细粒剂的制备方法
JP2020172486A (ja) * 2019-04-10 2020-10-22 参天製薬株式会社 エピナスチン又はその塩を含有する水性医薬組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3008944A1 (de) * 1980-03-08 1981-09-24 C.H. Boehringer Sohn, 6507 Ingelheim Dibenzimidazoazepine, ihre herstellung und verwendung
EP0658340A1 (en) * 1993-12-17 1995-06-21 Unilever N.V. Oral compositions
JPH0827034A (ja) * 1994-07-14 1996-01-30 Nikken Chem Co Ltd エリスリトール含有内用液剤
JPH0952849A (ja) * 1995-06-06 1997-02-25 Taisho Pharmaceut Co Ltd 感冒剤用組成物
DE19542281C2 (de) * 1995-11-14 1997-12-04 Boehringer Ingelheim Kg Verwendung von Epinastin für die Behandlung der Migräne
JPH1045576A (ja) * 1996-08-05 1998-02-17 Taisho Pharmaceut Co Ltd 鼻炎用内服薬
AU9187598A (en) * 1997-09-30 1999-04-23 Daiichi Pharmaceutical Co., Ltd. Oral preparation
JPH11302189A (ja) * 1998-04-21 1999-11-02 Taisho Pharmaceut Co Ltd 感冒用組成物
JP4731777B2 (ja) * 1999-10-12 2011-07-27 マルホ株式会社 経口医薬組成物

Also Published As

Publication number Publication date
EP1448204A1 (en) 2004-08-25
JP2010132702A (ja) 2010-06-17
BR0213488A (pt) 2004-11-03
DE10152973A1 (de) 2003-05-08
JP4564749B2 (ja) 2010-10-20
MXPA04003772A (es) 2004-07-30
KR20050034619A (ko) 2005-04-14
WO2003037350A1 (en) 2003-05-08
ECSP045087A (es) 2004-06-28
JP2005508364A (ja) 2005-03-31

Similar Documents

Publication Publication Date Title
ES2537334T3 (es) Formulación farmacéutica líquida para suministrar nicotina en la cavidad oral del sujeto
RU2000127710A (ru) Твердая быстроразлагающаяся шипучая композиция для орального применения и способ ее получения
ES2224634T3 (es) Formulacion oral que comprende biguanida y un acido organico.
JP2014509645A5 (es)
CO5580751A2 (es) Nueva formulacion de jarabe de epinastina seco y acuoso
HRP20161228T1 (hr) Vrećica s nikotinom u obliku slobodne soli
JP2009517384A5 (es)
AR073793A1 (es) Formulacion farmaceutica liquida que contiene paracetamol. excipiente liquido
AR069128A1 (es) Forma de dosificacion que se desintegra oralmente y proceso de preparacion
BR9709452B1 (pt) sistema de liberaÇço bucal na forma de uma pastilha degastÁvel.
BRPI0406996A (pt) Formas de dosagem sólida via transmucosa oral sem açúcar e sua utilização
JP2018523635A5 (es)
HRP20110482T1 (hr) Sastavi koji sadrže nerameksan
JP2013540795A (ja) 苦味のある薬物のための経口用医薬フィルム製剤
ES2555462T3 (es) Composiciones acuosas que comprenden arbekacina
EP2393478B1 (en) Taste and odor masked pharmaceutical compositions with high bioavailability
RU2016130051A (ru) Жидкие композиции рацекадотрила
ES2224869A1 (es) Composiciones farmaceuticas con actividad antibiotica.
ES2312921T3 (es) Disolucion acuosa concentrada de ambroxol.
HRP20211247T1 (hr) Pastila
LV12250B (en) PHARMACEUTICAL COMPOSITIONS ON DICLOFENAKA BASE
ES2211546T3 (es) Solucion oral de prucaloprida.
ES2215025T3 (es) Formulacion farmaceutica efervescente, que contiene metamizol.
UY26925A1 (es) Sistemas saborizantes para composiciones farmacéuticas y métodos para hacer dichas composiciones
ES2392967T3 (es) Formulaciones mejoradas que contienen derivados de imidazol sustituido

Legal Events

Date Code Title Description
FA Application withdrawn